Article Text

Download PDFPDF

A simple scoring system predicted clinical progression in HIV patients receiving highly active antiretroviral therapy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 QUESTION: In patients with HIV who are receiving highly active antiretroviral therapy (HAART), does a scoring system predict clinical progression?


Prognostic scoring system developed in 1 derivation cohort and validated in 2 cohorts of patients.


60 centres in Europe and Israel.


2027 patients (median age 37 y) formed the derivation set: inception cohort of participants in the EuroSIDA study who were ≥ 16 years of age and had started a protease inhibitor or non-nucleoside reverse-transcriptase inhibitor as part of a HAART antiretroviral regimen and had CD4 cell counts and viral loads measured within 6 months before starting HAART and ≥ 1 measurement after starting HAART. 2 cohorts of patients formed the validation set: 1946 patients in the EuroSIDA study who started HAART before recruitment to the study and 1442 patients from a clinic in Barcelona who had previously started HAART.

Description of prediction guide

Cox proportional hazards models were used to determine factors associated with clinical progression. The final prediction model comprised …

View Full Text